Ocera Therapeutics Inc (OCRX) 6.27 $OCRX
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 8:29AM CST
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
OCRX: 6.27 (-0.16)
The Stage Is Set For Investors To Realize Huge Gains With Ocera Therapeutics
BioCourse AP - at Seeking Alpha - Tue Jan 06, 9:23AM CST
OCRX: 6.27 (-0.16)
Nasdaq stocks posting largest percentage increases
AP - Wed Dec 31, 6:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 16.62 (-1.38), CYTK: 7.78 (+1.29), SIGM: 6.69 (-0.19), SIBC: 21.10 (+0.22), IDSA: 5.82 (-0.08), OCRX: 6.27 (-0.16), DJCO: 188.02 (+0.02)
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
GlobeNewswire - Wed Dec 03, 7:10AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as chief financial officer.
OCRX: 6.27 (-0.16)
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:48AM CST
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
OCRX: 6.27 (-0.16)
Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical
M2 - Tue Nov 25, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6f6s/global_irritable) has announced the addition of the "Global Irritable Bowel Syndrome Market 2015-2019" report to their offering. One major trend upcoming in this market is an increase in public awareness about irritable bowel syndrome, which is expected to increase the number of treatment-seeking patients, thereby increasing the consumption of medications. Growing public awareness increases the number of treatment-seeking patients, thereby leading to increased consumption of approved medications. According to the report, the presence of huge unmet needs in the field of irritable bowel syndrome is one of the major drivers of the market. There is a lack of a significant number of drugs approved by the FDA, and the use of generics and off-label drugs causes erosion in the market share of labeled products. This provides vendors with an opportunity to produce new drugs, which can give them an edge over others and hence, grab a major portion of the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Market Segmentation by Mechanism of Action 09. Market Segmentation by Dosage Form 10. Market Segmentation by Indication 11. Market Segmentation by End User Gender 12. Geographical Segmentation 13. Rate of Incidence and Prevalence 14. Buying Criteria 15. Market Growth Drivers 16. Drivers and their Impact 17. Market Challenges 18. Impact of Drivers and Challenges 19. Market Trends 20. Trends and their Impact 21. Vendor Landscape 22. Pipeline Portfolio 23. Key Vendor Analysis 24. Other Reports in this Series Companies Mentioned: - Abbott - Actavis - Alba Therapeutics - Alfa Wassermann - Alizyme - Almirall - AltheRx - Ardelyx - Astellas Pharma - AstraZeneca - Bayer - Bristol Myers Squibb - Dainippon Sumitomo Pharma - Dong-A Socio Holdings - DraisPharmaceuticals - Dynogen - GlaxoSmithKline - Hanmi - ImmusanT - Ironwood - Janssen - Lexicon - Menarini - MicroDose Therapeutx - Nestle - Norgine - Novartis - Ocera Therapeutics - Ono Pharmaceutical - ParPharmaceutical For more information visit http://www.researchandmarkets.com/research/8z..._irritable
OCRX: 6.27 (-0.16), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Ocera up again today
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 12:29PM CST
OCRX: 6.27 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.83 (+0.03), CLRB: 2.45 (+0.28), MPX: 8.13 (+0.31), FATE: 5.00 (-0.07), TTPH: 35.18 (-0.73), PHMD: 1.68 (+0.04), BIND: 6.06 (+0.21), AXPW: 0.39 (-0.04), CANF: 3.85 (+0.05), SYN: 2.13 (+0.18), RNA: 18.65 (unch), CLIR: 7.26 (-0.08), VSCI: 0.47 (unch), OCRX: 6.27 (-0.16), GALE: 1.68 (+0.06), REI: 10.00 (+0.27), OGEN: 0.91 (+0.16), PTP: 76.57 (-0.13), FPRX: 24.63 (+0.63)
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 8:46AM CST
Ocera Therapeutics (OCRX) was a big mover last session, with shares rising over 9% on the day.
BIIB: 391.66 (-0.45), OCRX: 6.27 (-0.16), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Ocera Therapeutics' (OCRX) CEO Linda Grais on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:47PM CST
OCRX: 6.27 (-0.16)
Ocera Therapeutics beats by $0.16
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:18PM CST
OCRX: 6.27 (-0.16)
Ocera Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced recent business highlights and reported financial results for the quarter ended September 30, 2014.
OCRX: 6.27 (-0.16)
Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Mon Nov 10, 7:42AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the Stifel 2014 Healthcare Conference being held at the Palace Hotel in New York, NY. Ocera's presentation is scheduled for Wednesday, November 19, 2014 at 3:00 PM ET in the Homes II conference room.
OCRX: 6.27 (-0.16)
Hepatic Encephalopathy Therapeutics Pipeline Review 2014 - 4 Companies & 5 Drug Profiles
M2 - Thu Nov 06, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/pccbnw/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Alfa Wassermann S.p.A - Umecrine Cognition AB Drug Profiles - rifaximin - glycerol phenylbutyrate - ornithine phenylacetate - THDP-17 - CVXL-0060 For more information visit http://www.researchandmarkets.com/research/pccbnw/hepatic
OCRX: 6.27 (-0.16), HPTX: 26.83 (-0.05)
Ocera Therapeutics to Announce Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its third quarter 2014 financial results on Thursday, November 13, 2014 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Thursday, November 13, 2014 at 4:30 p.m. Eastern Time.
OCRX: 6.27 (-0.16)
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 13 Annual BIO Investor Forum being held at the Palace Hotel in San Francisco, California. Ocera's presentation is scheduled for Tuesday, October 7, 2014 at 3:00 PM PT in the Presidio conference room.
OCRX: 6.27 (-0.16)
Ocera Therapeutics adds Steven P. James to board
M2 - Fri Sep 19, 6:26AM CDT
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Thursday the election of Steven P. James to its board of directors.
OCRX: 6.27 (-0.16)
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 8:29AM CST
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
OCRX: 6.27 (-0.16)
The Stage Is Set For Investors To Realize Huge Gains With Ocera Therapeutics
BioCourse AP - at Seeking Alpha - Tue Jan 06, 9:23AM CST
OCRX: 6.27 (-0.16)
Nasdaq stocks posting largest percentage increases
AP - Wed Dec 31, 6:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 16.62 (-1.38), CYTK: 7.78 (+1.29), SIGM: 6.69 (-0.19), SIBC: 21.10 (+0.22), IDSA: 5.82 (-0.08), OCRX: 6.27 (-0.16), DJCO: 188.02 (+0.02)
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
GlobeNewswire - Wed Dec 03, 7:10AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as chief financial officer.
OCRX: 6.27 (-0.16)
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:48AM CST
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
OCRX: 6.27 (-0.16)
Global Irritable Bowel Syndrome Market 2015-2019: Key Vendors are Actavis, Astellas Pharma, Nestle and Takeda Pharmaceutical
M2 - Tue Nov 25, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6f6s/global_irritable) has announced the addition of the "Global Irritable Bowel Syndrome Market 2015-2019" report to their offering. One major trend upcoming in this market is an increase in public awareness about irritable bowel syndrome, which is expected to increase the number of treatment-seeking patients, thereby increasing the consumption of medications. Growing public awareness increases the number of treatment-seeking patients, thereby leading to increased consumption of approved medications. According to the report, the presence of huge unmet needs in the field of irritable bowel syndrome is one of the major drivers of the market. There is a lack of a significant number of drugs approved by the FDA, and the use of generics and off-label drugs causes erosion in the market share of labeled products. This provides vendors with an opportunity to produce new drugs, which can give them an edge over others and hence, grab a major portion of the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Market Segmentation by Mechanism of Action 09. Market Segmentation by Dosage Form 10. Market Segmentation by Indication 11. Market Segmentation by End User Gender 12. Geographical Segmentation 13. Rate of Incidence and Prevalence 14. Buying Criteria 15. Market Growth Drivers 16. Drivers and their Impact 17. Market Challenges 18. Impact of Drivers and Challenges 19. Market Trends 20. Trends and their Impact 21. Vendor Landscape 22. Pipeline Portfolio 23. Key Vendor Analysis 24. Other Reports in this Series Companies Mentioned: - Abbott - Actavis - Alba Therapeutics - Alfa Wassermann - Alizyme - Almirall - AltheRx - Ardelyx - Astellas Pharma - AstraZeneca - Bayer - Bristol Myers Squibb - Dainippon Sumitomo Pharma - Dong-A Socio Holdings - DraisPharmaceuticals - Dynogen - GlaxoSmithKline - Hanmi - ImmusanT - Ironwood - Janssen - Lexicon - Menarini - MicroDose Therapeutx - Nestle - Norgine - Novartis - Ocera Therapeutics - Ono Pharmaceutical - ParPharmaceutical For more information visit http://www.researchandmarkets.com/research/8z..._irritable
OCRX: 6.27 (-0.16), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Ocera up again today
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 12:29PM CST
OCRX: 6.27 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.83 (+0.03), CLRB: 2.45 (+0.28), MPX: 8.13 (+0.31), FATE: 5.00 (-0.07), TTPH: 35.18 (-0.73), PHMD: 1.68 (+0.04), BIND: 6.06 (+0.21), AXPW: 0.39 (-0.04), CANF: 3.85 (+0.05), SYN: 2.13 (+0.18), RNA: 18.65 (unch), CLIR: 7.26 (-0.08), VSCI: 0.47 (unch), OCRX: 6.27 (-0.16), GALE: 1.68 (+0.06), REI: 10.00 (+0.27), OGEN: 0.91 (+0.16), PTP: 76.57 (-0.13), FPRX: 24.63 (+0.63)
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 8:46AM CST
Ocera Therapeutics (OCRX) was a big mover last session, with shares rising over 9% on the day.
BIIB: 391.66 (-0.45), OCRX: 6.27 (-0.16), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Ocera Therapeutics' (OCRX) CEO Linda Grais on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:47PM CST
OCRX: 6.27 (-0.16)
Ocera Therapeutics beats by $0.16
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:18PM CST
OCRX: 6.27 (-0.16)
Ocera Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced recent business highlights and reported financial results for the quarter ended September 30, 2014.
OCRX: 6.27 (-0.16)
Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Mon Nov 10, 7:42AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the Stifel 2014 Healthcare Conference being held at the Palace Hotel in New York, NY. Ocera's presentation is scheduled for Wednesday, November 19, 2014 at 3:00 PM ET in the Homes II conference room.
OCRX: 6.27 (-0.16)
Hepatic Encephalopathy Therapeutics Pipeline Review 2014 - 4 Companies & 5 Drug Profiles
M2 - Thu Nov 06, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/pccbnw/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Alfa Wassermann S.p.A - Umecrine Cognition AB Drug Profiles - rifaximin - glycerol phenylbutyrate - ornithine phenylacetate - THDP-17 - CVXL-0060 For more information visit http://www.researchandmarkets.com/research/pccbnw/hepatic
OCRX: 6.27 (-0.16), HPTX: 26.83 (-0.05)
Ocera Therapeutics to Announce Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:05PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its third quarter 2014 financial results on Thursday, November 13, 2014 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Thursday, November 13, 2014 at 4:30 p.m. Eastern Time.
OCRX: 6.27 (-0.16)
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 13 Annual BIO Investor Forum being held at the Palace Hotel in San Francisco, California. Ocera's presentation is scheduled for Tuesday, October 7, 2014 at 3:00 PM PT in the Presidio conference room.
OCRX: 6.27 (-0.16)
Ocera Therapeutics adds Steven P. James to board
M2 - Fri Sep 19, 6:26AM CDT
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Thursday the election of Steven P. James to its board of directors.
OCRX: 6.27 (-0.16)
